Complement protein C5 — Drug Target

All drugs that target Complement protein C5 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Complement C5 inhibitor

Marketed (1)

• Eculizumab (Soliris®) · Massachusetts General Hospital · Complement C5 inhibitor · Immunology
  Eculizumab is a monoclonal antibody that blocks complement protein C5, preventing the formation of the membrane attack complex and reducing complement-mediated cell destruction.

Phase 3 pipeline (1)

• Spacing of Eculizumab infusions · University Hospital, Tours · Complement C5 inhibitor · Immunology
  This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden.